Skip to content

Study · Case report or series · n = 1 · 2024

4 results

Significant elevation of serum CA19-9 and CA242 levels induced by dulaglutide.

Shi X

BMJ case reports6 May 2024

PMID38719260 (opens in a new tab)PMCIDPMC11085790 (opens in a new tab)DOI10.1136/bcr-2023-257657 (opens in a new tab)PepBankPUB-38719260
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanCase report or seriesSafety outcome

    In a woman with diabetes receiving dulaglutide, serum CA19-9 was markedly elevated without detected neoplasm.

    In plain wordsIn a woman with diabetes receiving dulaglutide, CA19-9 was markedly elevated, but examinations found no tumor.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseElevated CA19-9
    Study

    n = 1

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated · injection · 16 monthsAs given in this study (human).

    Source sentences

    Summary
    The patient presented with markedly elevated serum CA19-9 and CA242 levels revealed during a routine health examination despite being asymptomatic.
    4 context sentences
    Summary · context
    Imaging and interventional assessments did not reveal any hepatobiliary, gastrointestinal or pancreatic neoplasm.
    Summary · context
    After excluding alternate diagnoses, the patient was determined to exhibit an adverse reaction to dulaglutide use.
    Summary · context
    Here, we report the case of a woman in her mid-60s with diabetes for over 10 years.
    Summary · context
    She had been receiving dulaglutide injections for 16 months.
  2. 02HumanCase report or seriesSafety outcome

    In a woman with diabetes receiving dulaglutide, serum CA242 was markedly elevated without detected neoplasm.

    In plain wordsIn a woman with diabetes receiving dulaglutide, CA242 was markedly elevated, but examinations found no tumor.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseElevated CA242
    Study

    n = 1

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated · injection · 16 monthsAs given in this study (human).

    Source sentences

    Summary
    The patient presented with markedly elevated serum CA19-9 and CA242 levels revealed during a routine health examination despite being asymptomatic.
    4 context sentences
    Summary · context
    Imaging and interventional assessments did not reveal any hepatobiliary, gastrointestinal or pancreatic neoplasm.
    Summary · context
    After excluding alternate diagnoses, the patient was determined to exhibit an adverse reaction to dulaglutide use.
    Summary · context
    Here, we report the case of a woman in her mid-60s with diabetes for over 10 years.
    Summary · context
    She had been receiving dulaglutide injections for 16 months.
  3. 03HumanCase report or seriesSafety outcome

    In a woman with diabetes, serum CA19-9 normalized within 6 weeks after dulaglutide discontinuation.

    In plain wordsIn a woman with diabetes, CA19-9 returned to normal within 6 weeks after dulaglutide stopped.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseCA19-9 after discontinuation
    Study

    n = 1

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated · injection · 16 monthsAs given in this study (human).

    Measurements

    Time to normalisation of CA19-9
    ≤ 6 weeks
    after dulaglutide discontinuation

    Source sentences

    Summary
    Management involved the discontinuation of dulaglutide, which resulted in normalisation of serum CA19-9 and CA242 levels within 6 weeks.
    2 context sentences
    Summary · context
    Here, we report the case of a woman in her mid-60s with diabetes for over 10 years.
    Summary · context
    She had been receiving dulaglutide injections for 16 months.
  4. 04HumanCase report or seriesSafety outcome

    In a woman with diabetes, serum CA242 normalized within 6 weeks after dulaglutide discontinuation.

    In plain wordsIn a woman with diabetes, CA242 returned to normal within 6 weeks after dulaglutide stopped.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseCA242 after discontinuation
    Study

    n = 1

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated · injection · 16 monthsAs given in this study (human).

    Measurements

    Time to normalisation of CA242
    ≤ 6 weeks
    after dulaglutide discontinuation

    Source sentences

    Summary
    Management involved the discontinuation of dulaglutide, which resulted in normalisation of serum CA19-9 and CA242 levels within 6 weeks.
    2 context sentences
    Summary · context
    Here, we report the case of a woman in her mid-60s with diabetes for over 10 years.
    Summary · context
    She had been receiving dulaglutide injections for 16 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.